Quantcast
Home > Quotes > ITCI

Intra-Cellular Therapies Inc. Common Stock (ITCI) Quote & Summary Data

ITCI 
$13.97
*  
0.35
2.57%
Get ITCI Alerts
*Delayed - data as of Feb. 15, 2019  -  Find a broker to begin trading ITCI now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
27.5
Today's High / Low
$ 13.98 / $ 13.57
Share Volume
243,874
50 Day Avg. Daily Volume
403,371
Previous Close
$ 13.62
52 Week High / Low
$ 25.82 / $ 10.21
Market Cap
764,526,844
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -2.65
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.04

Intraday Chart

Shares Traded

Share Volume:
243,874
50 Day Avg. Daily Volume:
403,371

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.65

Trading Range

The current last sale of $13.97 is 36.83% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 13.98 $ 25.82
 Low: $ 13.57 $ 10.21

Company Description (as filed with the SEC)

We are a biopharmaceutical company focused on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Lumateperone (also known as ITI-007) is our lead product candidate with mechanisms of action that, we believe, may represent an effective treatment across multiple therapeutic indications. In our preclinical and clinical trials to date, lumateperone combines potent serotonin 5-HT2A receptor antagonism, dopamine receptor phosphoprotein modulation, or DPPM, glutamatergic modulation, and serotonin reuptake inhibition into a single drug candidate for the treatment of acute and residual schizophrenia and for the treatment of bipolar disorder, including bipolar depression.  ... More ...  


Risk Grade

Where does ITCI fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 13.74
Open Date:
Feb. 15, 2019
Close Price:
$ 13.97
Close Date:
Feb. 15, 2019

Consensus Recommendation

Analyst Info